Effects of cannabidiol on cannabis concentrate users

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effects of plant-derived cannabidiol (CBD) on individuals who regularly use cannabis concentrates but are not attempting to reduce their use. It is a randomized, placebo-controlled, dose-ranging study involving 120 adult participants who will take either 200 mg or 400 mg of CBD or a placebo daily for four weeks. Participants will engage in sessions at a mobile laboratory where their cannabis use, subjective effects, and cannabinoid levels will be monitored. The study aims to determine if CBD can reduce cannabis concentrate use and cravings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 25-60.
2. Regular use (at least 4 times per week) of cannabis concentrates for the last year.
3. Not currently seeking to cut down or stop cannabis use.
4. At least one episode of 3 consecutive days of cannabis abstinence with no experience of severe withdrawal symptoms (i.e., \>=4 DSM-5 Cannabis Withdrawal symptoms rated as "severe"), in the last 90 days.
5. At least two symptoms of a DSM-5 cannabis use disorder.

Exclusion Criteria:

1. Use of any illicit substance besides alcohol, nicotine, or cannabis (e.g., cocaine, opiates, methamphetamine, MDMA, benzodiazepines, or barbiturates) in the past 60 days, as indicated by self-report and urine toxicology screening at the beginning of each study visit.
2. Use of CBD-containing products other than cannabis concentrates in the past 90 days.
3. Alcohol use on 3 or more days per week, and/or \> 3 drinks per drinking day in the past 60 days. Participants must also have a breath alcohol level of 0 at the beginning of each study visit.
4. Daily nicotine use.
5. Meets DSM-5 diagnostic criteria for a psychotic disorder (e.g., schizophrenia, schizophreniform disorder, schizoaffective disorder), bipolar disorder, or major depression with suicidal ideation, or has a history of treatment for these disorders.
6. Current cardiovascular or respiratory disease (e.g., coronary artery disease, severe asthma, chronic obstructive pulmonary disease, etc.)
7. Current use of any psychotropic (e.g., antidepressants, anxiogenics) or hepatotoxic medications.
8. Currently use of anti-epileptic medications (e.g., clobazam, sodium valproate) or medications known to have major interactions with Epidiolex (buprenorphine, leflunomide, levomethadyl acetate, lomitapide, mipomersen, pexidartinib, propoxyphene, sodium oxybate, and/or teriflunomide) or a history of seizures.
9. Current use of strong or moderate CYP3A4 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include protease inhibitors, macrolide antibiotics \[e.g., erythromycin\], azole antifungals \[e.g., ketoconazole\], verapamil, and grapefruit juice).
10. Current use of strong or moderate CYP2C19 inhibitors or inducers (commonly used examples not captured by other exclusion criteria include proton pump inhibitors, prednisone, and norethisterone).
11. Current or past hepatocellular disease, as indicated by medical history or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 2 times the upper limit of the normal range at screening.
12. For female participants, pregnancy or trying to become pregnant. A positive pregnancy test at the beginning of any study visit will result in exclusion from ongoing study participation.
13. For female participants, currently lactating.
14. For female patients of childbearing potential, not willing to use at least an approved method of birth control while taking the study medication, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal (one year).
15. Current suicidality risk as indicated during the conduct of the C-SSRS with concurrence after a study physician's or PI evaluation if the response to C-SSRS questions 1 or 2 is "yes".

Where it's running

• University of Colorado Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting

Study contacts

• Principal investigator: Joseph P Schacht, PhD — University of Colorado, Denver
• Study coordinator: Joseph P Schacht, PhD
• Email: joseph.schacht@cuanschutz.edu
• Phone: 303-724-3773

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can tACS modulate motivation and reward signals in cannabis use disorder and depression

  We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.

  Recruiting Florida State University · Tallahassee, Florida and 1 other locations · NCT07924852

• Sex differences in how cannabis affects people who regularly use it

  This Phase 2 trial tests whether men and women who use cannabis several days a week respond differently to THC versus placebo.

  Recruiting Phase 2 Medical University of South Carolina · Charleston, South Carolina · NCT07815691

• Semaglutide for cannabis use disorder: see if a medicine helps reduce use

  This study tests whether weekly injections of semaglutide can help adults with cannabis use disorder reduce their cannabis use compared with placebo.

  Recruiting Phase 2 Psychiatric Centre Rigshospitalet · Frederiksberg · NCT07523633

• Brain imaging to predict teens' response to cannabis treatment

  This project will test whether teens' brain activity during a learning task can predict how well 14–17-year-olds do in a 10-week virtual reward program to reduce cannabis use.

  Recruiting Indiana University · Indianapolis, Indiana · NCT07340554

• Reducing cannabis use to improve daily functioning.

  This program will try an 8-week combination of motivational interviewing, computerized CBT (CBT4CBT), and small financial rewards to help adults with cannabis use disorder cut back on cannabis.

  Recruiting Medical University of South Carolina · Charleston, South Carolina · NCT07218471

• Home-based brain stimulation with guided mindfulness for cannabis use disorder

  This project tests whether daily at-home mild brain stimulation plus guided mindfulness can help adults with cannabis use disorder reduce or stop their cannabis use.

  Recruiting NYU Langone Health · New York, New York · NCT07184983

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.